Diligence memo · auto-generated · as of July 3, 2026
Sulfagenix, Inc.
Sulfagenix, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Sulfagenix, Inc. operates in Biotechnology, based in CHESTERLAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sulfagenix, Inc. has raised $2.6M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.3M on 2014-11-13.
Most recent recorded round closed around 2014-11-13.
Valuation (modeled)modeled
Provath models Sulfagenix, Inc. at approximately $60M (range $972K–$470M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.90× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era. Within the normal band (90% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 11.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 32% of Biotechnology peers (4293 compared).
Modeled value ranks above 49% of those peers.
Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.